You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Mass. Movers

Idera surges on positive drug-test results

Cambridge-based Idera Pharmaceuticals Inc. reported its lead drug candidate, for moderate to severe plaque psoriasis, was more effective than a placebo in a Phase 2a clinical trial. Idera said 48 percent of patients with the condition (12 of 25) treated with IMO-3100 demonstrated improvement. The trial involved two dose levels of the drug administered for four weeks, with a four-week follow-up. None of the 12 patients who got placebos showed significant improvement.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week